MARKET

MTFB

MTFB

Motif Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1410
+0.0027
+1.95%
Closed 16:00 11/12 EST
OPEN
0.1452
PREV CLOSE
0.1383
HIGH
0.1600
LOW
0.1380
VOLUME
431.03K
TURNOVER
--
52 WEEK HIGH
11.50
52 WEEK LOW
0.1269
MARKET CAP
48.29M
P/E (TTM)
-3.5516
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MTFB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MTFB News

  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.4d ago
  • The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study
  • Benzinga.10/29 11:32
  • The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings
  • Benzinga.10/15 11:50
  • The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
  • Benzinga.10/11 12:14

More

Industry

Biotechnology & Medical Research
+0.45%
Pharmaceuticals & Medical Research
+0.31%

Hot Stocks

Name
Price
%Change

About MTFB

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It intends to build a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and is pursuing programs in various stages of development.
More

Webull offers Motif Bio PLC (MTFB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.